2. GPCR/G Protein Neuronal Signaling
  3. Dopamine Receptor Adrenergic Receptor
  4. Bulbocapnine

Bulbocapnine is an aporphine isoquinoline alkaloid that exerts antagonistic effects on dopamine Receptor) and α-adrenergic receptors, as well as anti-peroxidative effects. The Ki value of bulbocapnine for tyrosine hydroxylase (TH) is 0.20 mM. Bulbocapnine reduces intracellular dopamine content, inhibits TH activity, and decreases Ca2+ concentration. Bulbocapnine antagonizes the dose-dependent inhibitory effect of dopamine on the heart rate acceleration induced by stimulating the postganglionic fibers of the right cardiac accelerator nerve.

For research use only. We do not sell to patients.

Bulbocapnine

Bulbocapnine Chemical Structure

CAS No. : 298-45-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Bulbocapnine Related Antibodies

Top Publications Citing Use of Products

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms
Dopamine Receptor D1 Receptor D2 Receptor D3 Receptor D4 Receptor D5 Receptor

View All Adrenergic Receptor Isoform Specific Products:

View All Isoforms
α adrenergic receptor β adrenergic receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Bulbocapnine is an aporphine isoquinoline alkaloid that exerts antagonistic effects on dopamine Receptor) and α-adrenergic receptors, as well as anti-peroxidative effects. The Ki value of bulbocapnine for tyrosine hydroxylase (TH) is 0.20 mM. Bulbocapnine reduces intracellular dopamine content, inhibits TH activity, and decreases Ca2+ concentration. Bulbocapnine antagonizes the dose-dependent inhibitory effect of dopamine on the heart rate acceleration induced by stimulating the postganglionic fibers of the right cardiac accelerator nerve[1][2].

Cellular Effect
Cell Line Type Value Description References
PC-12 IC50
27 μM
Compound: 4, (S)-Bulbocapnine
Reduction of dopamine level in catecholamine-inducing rat PC12 cells
Reduction of dopamine level in catecholamine-inducing rat PC12 cells
[PMID: 17228858]
In Vitro

Bulbocapnine (5-40 μM; 6-60 h) dose-dependently reduces dopamine content in PC12 cells, with an IC50 of 26.7 μM[2].
Bulbocapnine (20 μM; 6-12 h) inhibits TH activity by 24.4% and reduces Ca2+ concentration by 12.9% in PC12 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bulbocapnine Related Antibodies
Parmacokinetics
Species Dose Route AUC Bioavailability Cmax Tmax
Rat[2] 10 mg/kg p.o. / / 26 μg/mL 4 h
Rat[2] 3.2 mg/kg p.o. 126 μg·h/mL 91 % 12 μg/mL 2 h
Rat[2] 3.2 mg/kg i.v. 125 μg·h/mL 91 % / /
Dog[2] 1.0 mg/kg p.o. 99 μg·h/mL 72 % 2.5 μg/mL 1.5 h
Dog[2] 1.0 mg/kg i.v. 108 μg·h/mL 78 % / /
Monkey[2] 5.0 mg/kg p.o. 207 μg·h/mL 52 % 16 μg/mL 2 h
Monkey[2] 5.0 mg/kg i.v. 280 μg·h/mL 54 % / /
In Vivo

Bulbocapnine (5 mg/kg; i.v.; single dose) significantly antagonizes the adrenergic inhibitory actions of M-7, apomorphine, N,N-dimethyldopamine, and cocaine-potentiated dopamine on cardioaccelerator nerve-induced heart rate increases, reduces the pressor response to N,N-dimethyldopamine, but does not antagonize dopamine's pressor response or alter cocaine-modified dopamine chronotropic effects[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: (weight 2-4 kg; anesthetized)[1]
Dosage: 5 mg/kg
Administration: i.v.; single dose
Result: Significantly antagonized the inhibitory effects of M-7, apomorphine, and N,N-dimethyldopamine on heart rate tachycardia induced by neurostimulation.
Significantly reduced the increase in blood pressure induced by N,N-dimethyldopamine.
Molecular Weight

325.36

Formula

C19H19NO4
CAS No.
SMILES

OC1=C2C3=C(OCO4)C4=CC5=C3[C@](N(CC5)C)([H])CC2=CC=C1OC
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bulbocapnine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bulbocapnine298-45-3Dopamine ReceptorAdrenergic ReceptorBeta Receptoraporphine isoquinoline alkaloiddopamine Receptorantagonisticα-adrenergic receptorsantagonisticantiperoxidantPC12 cellsCat
Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bulbocapnine
Cat. No.:
HY-N18279
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.